ArticleFrontiers in cellular and infection microbiology2025
Vγ9Vδ2 T cells expanded with vitamin C combined with HMBPP
Article in Frontiers in cellular and infection microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- From bench to bedside: advances in cell therapy for tuberculosis treatment.Stem cell research & therapy · 2026Review
- Vγ9Vδ2 T cells in tuberculosis: protective immunity and translational perspectives.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Methods: Venous blood was collected from healthy individuals, and PBMCs were subsequently isolated. In vitro, Vγ9Vδ2 T cells were selectively expanded with HMBPP, rIL-2, and VC. Flow cytometry was utilized to analyze the purities and phenotypes of Vγ9Vδ2 T cells, while cell counts were performed to determine the total number of viable cells. Magnetic bead sorting was employed to purify Vγ9Vδ2 T cells. Results: VC (70 μM) significantly enhances the expansion of Vγ9Vδ2 T cells within PBMCs during primary HMBPP activation in the presence of rIL-2, with higher induction rates and total cell proliferation. By day 14 of induction, Vγ9Vδ2 T cells expanded with HMBPP, VC, and rIL-2 exhibited the central memory (10-20%) and the effector memory phenotypes (75-90%). Furthermore, these expanded T cells effectively inhibited the growth of intracellular virulent Conclusion: This study demonstrates that VC enhances the proliferative expansion of Vγ9Vδ2 T cells in PBMCs primarily stimulated with HMBPP and rIL-2. The expanded Vγ9Vδ2 T cells are capable of effectively inhibiting the growth of virulent H37Rv strain, likely through the secretion of TNF-α and IFN-γ. These findings provide a novel direction for tuberculosis treatment research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.